{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:24:45Z","timestamp":1790421885733,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/deed.de"}],"funder":[{"DOI":"10.13039\/501100018935","name":"Universit\u00e4tsklinikum Erlangen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018935","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Hintergrund<\/jats:title>\n                    <jats:p>Chim\u00e4re Antigenrezeptor(CAR)-T-Zellen haben sich als effektive Therapieoption in der Behandlung von B\u2011Zell-assoziierten Malignomen etabliert. Neben malignen B\u2011Zellen k\u00f6nnen auch autoreaktive B\u2011Zellen ein Ziel der anti-CD19-gerichteten CAR-T-Zellen (CD19-CAR-T-Zellen) darstellen. B\u2011Zellen sind beim systemischen Lupus erythematodes (SLE) ma\u00dfgeblich an der Produktion pathogener Autoantik\u00f6rper beteiligt und f\u00f6rdern sowohl den Krankheitsausbruch als auch das Fortschreiten der Erkrankung. In unseren bisherigen Forschungsarbeiten als auch in weiteren Fallanalysen konnte gezeigt werden, dass der Einsatz der CD19-CAR-T-Zell-Therapie bei schwerem, therapierefrakt\u00e4rem Verlauf des SLE eine vielversprechende Wirksamkeit sowie ein akzeptables Sicherheitsprofil aufweist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ziel der Arbeit<\/jats:title>\n                    <jats:p>Es wird ein Fazit zum aktuellen Stand bez\u00fcglich Wirksamkeit und Sicherheit der CD19-CAR-T-Zell-Therapie beim systemischen Lupus erythematodes (SLE) gegeben.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Material und Methode<\/jats:title>\n                    <jats:p>PatientInnen mit progredientem, therapierefrakt\u00e4rem SLE erhielten im Rahmen eines individuellen Heilversuches eine autologe CD19-CAR-T-Zell-Therapie (MB19,1, Miltenyi Biotec, Bergisch Gladbach, Deutschland) und werden regelm\u00e4\u00dfig an unserem Zentrum nachbeobachtet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ergebnisse<\/jats:title>\n                    <jats:p>Elf PatientInnen mit progredientem, therapierefrakt\u00e4rem SLE erhielten im Rahmen eines individuellen Heilversuches eine autologe CD19-CAR-T-Zell-Therapie. Die mediane Nachbeobachtungszeit betr\u00e4gt 2,5\u00a0Jahre (0,5 bis 4\u00a0Jahre). Alle PatientInnen erreichten innerhalb von 6\u00a0Monaten eine DORIS-Remission (Definition of Remission in SLE). Die immunsuppressive Therapie wurde bei allen PatientInnen vollst\u00e4ndig abgesetzt. F\u00fcnf der 11\u00a0PatientInnen hatten ein \u201ecytokine release syndrome\u201c (CRS) ersten Grades. CRS Grad\u00a02 wurde nur 1\u2011malig beobachtet. H\u00f6hergradige CRS sind in dieser Kohorte nicht aufgetreten. Bei unseren SLE-PatientInnen war keine Neurotoxizit\u00e4t (\u201eimmune effector cell-associated neurotoxicity syndrome\u201c [ICANS]) festzustellen. Alle PatientInnen befinden sich aktuell in einer anhaltenden und medikamentenfreien Remission. Wir verzeichneten bei einer Patientin einen therapiebed\u00fcrftigen SLE-Schub. Erste Daten deuten trotz \u00e4hnlicher CD19-CAR-T-Zell-Expansion und Kinetik auf ein besseres Sicherheitsprofil der CD19-CAR-T-Zell-Therapie bei SLE im Vergleich zu Lymphomkohorten hin. Bei SLE-Patientinnen stellt sich die adaptive Immunit\u00e4t nach einer CD19-CAR-T-Zell-Therapie zudem schnell wieder her.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Schlussfolgerungen<\/jats:title>\n                    <jats:p>Der Einsatz von CD19-CAR-T-Zellen bei PatientInnen mit schwerem Verlauf des SLE erweist sich als sicher und wirksam.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00393-025-01705-0","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T11:35:21Z","timestamp":1756985721000},"page":"612-620","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Langzeitverlauf von Effizienz und Sicherheit der CD19-CAR T-Zell-Therapie beim systemischen Lupus erythematodes","Long-term follow up of efficiency and safety of CD19-CAR T-cell treatment of systemic lupus erythematosus"],"prefix":"10.1007","volume":"84","author":[{"given":"Jule","family":"Taubmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"B\u00f6ltz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Hagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Wirsching","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"V\u00f6lkl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Kharboutli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Sp\u00f6rl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Garantziotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Grieshaber-Bouyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Mackensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"issue":"50","key":"1705_CR1","doi-asserted-by":"publisher","first-page":"25222","DOI":"10.1073\/pnas.1908576116","volume":"116","author":"P Mistry","year":"2019","unstructured":"Mistry\u00a0P, Nakabo\u00a0S, O\u2019Neil\u00a0L, Goel\u00a0RR, Jiang\u00a0K, Carmona-Rivera\u00a0C et\u00a0al (2019) Transcriptomic, epigenetic, and functional analyses implicate neutrophil diversity in the pathogenesis of systemic lupus erythematosus. Proc Natl Acad Sci USA 116(50):25222\u201325228","journal-title":"Proc Natl Acad Sci USA"},{"key":"1705_CR2","volume-title":"Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in arthritis and rheumatism","year":"2010","unstructured":"Pons-Estel\u00a0GJ, Alarc\u00f3n\u00a0GS, Scofield\u00a0L, Reinlib\u00a0L, Cooper\u00a0GS (Hrsg) (2010) Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in arthritis and rheumatism. Elsevier"},{"issue":"9","key":"1705_CR3","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41419-020-02928-6","volume":"11","author":"H Lou","year":"2020","unstructured":"Lou\u00a0H, Wojciak-Stothard\u00a0B, Ruseva\u00a0MM, Cook\u00a0HT, Kelleher\u00a0P, Pickering\u00a0MC et\u00a0al (2020) Autoantibody-dependent amplification of inflammation in SLE. Cell Death Dis 11(9):729","journal-title":"Cell Death Dis"},{"issue":"1","key":"1705_CR4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1002\/art.27233","volume":"62","author":"JT Merrill","year":"2010","unstructured":"Merrill\u00a0JT, Neuwelt\u00a0CM, Wallace\u00a0DJ, Shanahan\u00a0JC, Latinis\u00a0KM, Oates\u00a0JC et\u00a0al (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase\u00a0II\/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum Off J Am Coll Rheumatol 62(1):222\u2013233","journal-title":"Arthritis Rheum Off J Am Coll Rheumatol"},{"issue":"1","key":"1705_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/imr.12810","volume":"292","author":"SW Jackson","year":"2019","unstructured":"Jackson\u00a0SW, Davidson\u00a0A (2019) BAFF inhibition in SLE\u2014Is tolerance restored? Immunol Rev 292(1):102\u2013119","journal-title":"Immunol Rev"},{"issue":"6","key":"1705_CR6","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1093\/rheumatology\/key428","volume":"58","author":"TH Ramwadhdoebe","year":"2019","unstructured":"Ramwadhdoebe\u00a0TH, van Baarsen\u00a0LG, Boumans\u00a0MJ, Bruijnen\u00a0ST, Safy\u00a0M, Berger\u00a0FH et\u00a0al (2019) Effect of rituximab treatment on T and\u00a0B\u00a0cell subsets in lymph node biopsies of patients with rheumatoid arthritis. Rheumatology 58(6):1075\u20131085","journal-title":"Rheumatology"},{"issue":"12","key":"1705_CR7","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1016\/j.bbmt.2019.08.015","volume":"25","author":"T Jain","year":"2019","unstructured":"Jain\u00a0T, Bar\u00a0M, Kansagra\u00a0AJ, Chong\u00a0EA, Hashmi\u00a0SK, Neelapu\u00a0SS et\u00a0al (2019) Use of chimeric antigen receptor T\u00a0cell therapy in clinical practice for relapsed\/refractory aggressive B\u00a0cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305\u20132321","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"1705_CR8","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","volume":"29","author":"K Rejeski","year":"2023","unstructured":"Rejeski\u00a0K, Jain\u00a0MD, Smith\u00a0EL (2023) Mechanisms of resistance and treatment of relapse after CAR T\u2011cell therapy for large B\u2011cell lymphoma and multiple myeloma. Transplant Cell Ther 29(7):418\u2013428","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"1705_CR9","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S et\u00a0al (2024) CD19 CAR T\u2011cell therapy in autoimmune disease\u2014a case series with follow-up. N\u00a0Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"issue":"4","key":"1705_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/art.42784","volume":"76","author":"J Taubmann","year":"2024","unstructured":"Taubmann\u00a0J, M\u00fcller\u00a0F, Mutlu\u00a0YM, V\u00f6lkl\u00a0S, Aigner\u00a0M, Bozec\u00a0A et\u00a0al (2024) CD19 chimeric antigen receptor T\u00a0cell treatment: unraveling the role of B\u00a0cells in systemic lupus erythematosus. Arthritis Rheumatol 76(4):497\u2013504","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"1705_CR11","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","volume":"63","author":"J Taubmann","year":"2024","unstructured":"Taubmann\u00a0J, Knitza\u00a0J, M\u00fcller\u00a0F, V\u00f6lkl\u00a0S, Aigner\u00a0M, Kleyer\u00a0A et\u00a0al (2024) Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T\u00a0cells after failure of several B\u2011cell depleting antibodies. Rheumatology 63(1):e12\u2013e4","journal-title":"Rheumatology"},{"issue":"2","key":"1705_CR12","first-page":"e83","volume":"7","author":"J Auth","year":"2025","unstructured":"Auth\u00a0J, M\u00fcller\u00a0F, V\u00f6lkl\u00a0S, Bayerl\u00a0N, Distler\u00a0JH, Tur\u00a0C et\u00a0al (2025) CD19-targeting CAR T\u2011cell therapy in patients with diffuse systemic sclerosis: a\u00a0case series. Rheumatology 7(2):e83\u2013e93","journal-title":"Rheumatology"},{"issue":"10","key":"1705_CR13","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/ard-2024-225785","volume":"83","author":"W Wang","year":"2024","unstructured":"Wang\u00a0W, He\u00a0S, Zhang\u00a0W, Zhang\u00a0H, DeStefano\u00a0VM, Wada\u00a0M et\u00a0al (2024) BCMA-CD19 compound CAR T\u00a0cells for systemic lupus erythematosus: a\u00a0phase\u00a01 open-label clinical trial. Ann Rheum Dis 83(10):1304\u20131314","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"1705_CR14","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2023.8753","volume":"329","author":"A-C Pecher","year":"2023","unstructured":"Pecher\u00a0A\u2011C, Hensen\u00a0L, Klein\u00a0R, Schairer\u00a0R, Lutz\u00a0K, Atar\u00a0D et\u00a0al (2023) CD19-targeting CAR T\u00a0cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA 329(24):2154\u20132162","journal-title":"JAMA"},{"issue":"1","key":"1705_CR15","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur\u00a0C, Eckstein\u00a0M, Velden\u00a0J, Rauber\u00a0S, Bergmann\u00a0C, Auth\u00a0J et\u00a0al (2025) CD19-CAR T\u2011cell therapy induces deep tissue depletion of B\u00a0cells. Ann Rheum Dis 84(1):106\u2013114","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1705_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos\u00a0D, Kr\u00f6nke\u00a0G, V\u00f6lkl\u00a0S, Kretschmann\u00a0S, Aigner\u00a0M, Kharboutli\u00a0S et\u00a0al (2021) CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus. N\u00a0Engl J Med 385(6):567\u2013569","journal-title":"N Engl J Med"},{"issue":"10","key":"1705_CR17","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen\u00a0A, M\u00fcller\u00a0F, Mougiakakos\u00a0D, B\u00f6ltz\u00a0S, Wilhelm\u00a0A, Aigner\u00a0M et\u00a0al (2022) Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132","journal-title":"Nat Med"},{"issue":"8","key":"1705_CR18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller\u00a0F, Taubmann\u00a0J, Bucci\u00a0L, Wilhelm\u00a0A, Bergmann\u00a0C, V\u00f6lkl\u00a0S et\u00a0al (2024) CD19 CAR T\u2011Cell Therapy in Autoimmune Disease\u2014A Case Series with Follow-up. N\u00a0Engl J Med 390(8):687\u2013700","journal-title":"N Engl J Med"},{"key":"1705_CR19","unstructured":"Deutsche Gesellschaft f\u00fcr Rheumatologie und Klinische Immunologie e.\u202fV., S3\u00a0Leitlinie zum Management des systemischen Lupus erythematodes Version\u00a01.1. \nhttps:\/\/register.awmf.org\/de\/leitlinien\/detail\/060-008. Zugegriffen: 27.06.2025"},{"issue":"4","key":"1705_CR20","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee\u00a0DW, Santomasso\u00a0BD, Locke\u00a0FL, Ghobadi\u00a0A, Turtle\u00a0CJ, Brudno\u00a0JN et\u00a0al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625\u2013638","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"1705_CR21","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1182\/blood.2023020578","volume":"142","author":"K Rejeski","year":"2023","unstructured":"Rejeski\u00a0K, Subklewe\u00a0M, Aljurf\u00a0M, Bachy\u00a0E, Balduzzi\u00a0A, Barba\u00a0P et\u00a0al (2023) Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations. Blood 142(10):865\u2013877","journal-title":"Blood"},{"issue":"3","key":"1705_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"P Hayden","year":"2022","unstructured":"Hayden\u00a0P, Roddie\u00a0C, Bader\u00a0P, Basak\u00a0G, Bonig\u00a0H, Bonini\u00a0C et\u00a0al (2022) Management of adults and children receiving CAR T\u2011cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol 33(3):259\u2013275","journal-title":"Ann Oncol"},{"key":"1705_CR23","doi-asserted-by":"crossref","unstructured":"Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S et\u00a0al (2023) Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome. Transplant Cell Ther 29(7)","DOI":"10.1016\/j.jtct.2023.03.006"},{"issue":"9","key":"1705_CR24","doi-asserted-by":"publisher","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","volume":"30","author":"SDM Cordas dos","year":"2024","unstructured":"Cordas dos\u00a0SDM, Tix\u00a0T, Shouval\u00a0R, Gafter-Gvili\u00a0A, Alberge\u00a0J\u2011B, Cliff\u00a0ERS et\u00a0al (2024) A\u00a0systematic review and meta-analysis of nonrelapse mortality after CAR T\u00a0cell therapy. Nat Med 30(9):2667\u20132678","journal-title":"Nat Med"},{"issue":"10468","key":"1705_CR25","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.1016\/S0140-6736(24)02265-7","volume":"404","author":"M Hagen","year":"2024","unstructured":"Hagen\u00a0M, M\u00fcller\u00a0F, Wirsching\u00a0A, Kharboutli\u00a0S, Sp\u00f6rl\u00a0S, Aigner\u00a0M et\u00a0al (2024) Treatment of CNS systemic lupus erythematosus with CD19 CAR T\u00a0cells. Lancet 404(10468):2158\u20132160","journal-title":"Lancet"},{"issue":"10437","key":"1705_CR26","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau\u00a0T, Naumann-Bartsch\u00a0N, Aigner\u00a0M, Kharboutli\u00a0S, Kretschmann\u00a0S, Spoerl\u00a0S et\u00a0al (2024) CAR T\u2011cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet 403(10437):1627\u20131630","journal-title":"Lancet"},{"issue":"12","key":"1705_CR27","doi-asserted-by":"publisher","first-page":"e179433","DOI":"10.1172\/jci.insight.179433","volume":"9","author":"A Wilhelm","year":"2024","unstructured":"Wilhelm\u00a0A, Chambers\u00a0D, M\u00fcller\u00a0F, Bozec\u00a0A, Grieshaber-Bouyer\u00a0R, Winkler\u00a0T et\u00a0al (2024) Selective CAR T\u00a0cell-mediated B\u00a0cell depletion suppresses IFN signature in SLE. JCI Insight 9(12):e179433","journal-title":"JCI Insight"},{"key":"1705_CR28","doi-asserted-by":"publisher","unstructured":"M\u00fcller\u00a0F et\u00a0al. (2025) Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma. Blood. https:\/\/doi.org\/10.1182\/blood.2025028375","DOI":"10.1182\/blood.2025028375"},{"key":"1705_CR29","doi-asserted-by":"crossref","unstructured":"Hagen\u00a0M et\u00a0al (2025) Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study. The Lancet Rheumatology 7(6):e424\u2013e433","DOI":"10.1016\/S2665-9913(25)00091-8"},{"key":"1705_CR30","doi-asserted-by":"publisher","first-page":"e14157","DOI":"10.1111\/tid.14157","volume":"25","author":"E Kampouri","year":"2023","unstructured":"Kampouri\u00a0E, Little\u00a0JS, Rejeski\u00a0K, Manuel\u00a0O, Hammond\u00a0SP, Hill\u00a0JA (2023) Infections after chimeric antigen receptor (CAR)-T-cell therapy for hematologic malignancies. Transplant Infectious Dis 25:e14157","journal-title":"Transplant Infectious Dis"},{"issue":"8","key":"1705_CR31","first-page":"925","volume":"136","author":"JA Hill","year":"2020","unstructured":"Hill\u00a0JA, Seo\u00a0SK (2020) How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T\u00a0cells for B\u2011cell malignancies. Blood J Am Soc Hematol 136(8):925\u2013935","journal-title":"Blood J Am Soc Hematol"},{"issue":"7897","key":"1705_CR32","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/s41586-021-04390-6","volume":"602","author":"JJ Melenhorst","year":"2022","unstructured":"Melenhorst\u00a0JJ, Chen\u00a0GM, Wang\u00a0M, Porter\u00a0DL, Chen\u00a0C, Collins\u00a0MA et\u00a0al (2022) Decade-long leukaemia remissions with persistence of CD4+ CAR T\u00a0cells. Nature 602(7897):503\u2013509","journal-title":"Nature"},{"issue":"12","key":"1705_CR33","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/S1474-4422(23)00375-7","volume":"22","author":"A Haghikia","year":"2023","unstructured":"Haghikia\u00a0A, Hegelmaier\u00a0T, Wolleschak\u00a0D, B\u00f6ttcher\u00a0M, Desel\u00a0C, Borie\u00a0D et\u00a0al (2023) Anti-CD19 CAR T\u00a0cells for refractory myasthenia gravis. Lancet Neurol 22(12):1104\u20131105","journal-title":"Lancet Neurol"},{"issue":"18","key":"1705_CR34","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang\u00a0X, Wu\u00a0X, Tan\u00a0B, Zhu\u00a0L, Zhang\u00a0Y, Lin\u00a0L et\u00a0al (2024) Allogeneic CD19-targeted CAR\u2011T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890\u20134904","journal-title":"Cell"},{"issue":"1","key":"1705_CR35","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41392-024-01998-8","volume":"9","author":"D Mougiakakos","year":"2024","unstructured":"Mougiakakos\u00a0D (2024) Allogeneic CAR T\u00a0cells for autoimmune diseases: a\u00a0glimpse into the future. Signal Transduct Target Ther 9(1):276","journal-title":"Signal Transduct Target Ther"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01705-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00393-025-01705-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-025-01705-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T10:06:24Z","timestamp":1759313184000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00393-025-01705-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s00393-025-01705-0","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,4]]},"assertion":[{"value":"18 July 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Schett hat Vortragshonorare von BMS, Cabaletta, Janssen, Kyverna, Miltenyi und Novartis erhalten. A.\u00a0Mackensen hat Vortragshonorare und Beratungshonorare von BMS, Century Therapeutics, Celgene, Kyverna, Gilead, Janssen, Miltenyi und Novartis erhalten. J.\u00a0Taubmann, S.\u00a0B\u00f6ltz, M.\u00a0Hagen, A.\u00a0Wirsching, F.\u00a0M\u00fcller, S.\u00a0V\u00f6lkl, S.\u00a0Kharboutli, S.\u00a0Sp\u00f6rl, P.\u00a0Garantziotis, M.\u00a0Aigner und R.\u00a0Grieshaber-Bouyerb geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}